Emergent Biosolutions
EBS
198 hedge funds and large institutions have $524M invested in Emergent Biosolutions in 2022 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 87 increasing their positions, 49 reducing their positions, and 39 closing their positions.
78% more repeat investments, than reductions
Existing positions increased: 87 | Existing positions reduced: 49
47% more call options, than puts
Call options by funds: $877K | Put options by funds: $595K
11.04% more ownership
Funds ownership: 81.6% → 92.64% (+11%)
6% less funds holding
Funds holding: 211 → 198 (-13)
26% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 39
39% less capital invested
Capital invested by funds: $854M → $524M (-$330M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$23.2M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$17.7M |
| 3 |
D.E. Shaw & Co
New York
|
+$9.89M |
| 4 |
BlackRock
New York
|
+$8.68M |
| 5 |
Hotchkis & Wiley Capital Management
Los Angeles,
California
|
+$7.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Neuberger Berman Group
New York
|
-$14.4M |
| 2 |
GACM
Global Alpha Capital Management
Montreal,
Quebec, Canada
|
-$12.7M |
| 3 |
Fisher Asset Management
Camas,
Washington
|
-$10.5M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$8.45M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$5.93M |
EBS Hedge Fund Activity: Q4 2022 in Review
198 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q4 2022, worth a combined $524M — down 39% from $854M a quarter earlier.
Sellers outnumbered buyers: 39 funds closed out of EBS and 29 opened new positions — a net loss of 10 holders — while 49 trimmed existing stakes and 87 added.
The largest buyer was State Street, adding an estimated $23.2M. The largest seller was Neuberger Berman Group, exiting entirely with an estimated $14.4M sold.
- 198 institutional investors held Emergent Biosolutions (EBS) as of Q4 2022, down from 211 in Q3 2022.
- Funds reported $524M of Emergent Biosolutions stock for Q4 2022, down 39% quarter-over-quarter.
- 29 funds opened new Emergent Biosolutions positions in Q4 2022 and 39 closed out, a net change of -10 holders.
- The largest Emergent Biosolutions buyer in Q4 2022 was State Street, an estimated $23.2M added.
- The largest Emergent Biosolutions seller in Q4 2022 was Neuberger Berman Group, an estimated $14.4M sold.
Based on aggregated 13F filings for Q4 2022.